A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms
Copyright © 2023 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Cervicobrachial pain frequently affects the quality of life (QOL) of the general public and has a significant economic impact on the health care systems of various countries. There are a number of treatment options for this disease, including widely-used drug therapy, but the effectiveness of each option is indeterminate, and there have been no published cost-effectiveness analysis studies so far. This prospective observational study aimed to examine the cost-effectiveness of drug treatment for cervicobrachial symptoms.
METHODS: A 6-month medication regimen for each of five frequently-prescribed drugs for cervicobrachial symptoms was administered to 322 patients at 24 centers in Japan. Outcome measures, including of the EuroQol Group 5D, Short Form-8, and Visual Analog Scale (VAS), were investigated at baseline and every month thereafter. Incremental cost-effectiveness ratios (ICERs) of the drug cost to quality-adjusted life years (QALYs) were calculated. A stratified analysis of patient characteristics was also performed to identify baseline factors potentially affecting cost-effectiveness.
RESULTS: The ICER of entire drug treatment for cervicobrachial symptoms was 7,491,640 yen. Compared with the reference willingness-to-pay, the ICER was assumed to not be cost-effective. A certain number of QALYs were gained during the first 3 months after the treatment intervention, but almost no QALYs were gained during the following 3 months. Stratified analysis showed that cost-effectiveness was extremely low for patients with high baseline VAS and high QOL.
CONCLUSIONS: The available medications for cervicobrachial symptoms did not have excellent cost-effectiveness. Although a certain number of QALYs were gained during the first 3 months after medication, no QALYs were gained in the latter half of the study period, suggesting that it is not advisable to continue the medication needlessly.
LEVEL OF EVIDENCE: II, prospective cohort study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association - (2023) vom: 26. Dez. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Cervicobrachial symptoms |
|---|
| Anmerkungen: |
Date Revised 27.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jos.2023.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366420437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366420437 | ||
| 003 | DE-627 | ||
| 005 | 20231229124318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jos.2023.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM366420437 | ||
| 035 | |a (NLM)38151393 | ||
| 035 | |a (PII)S0949-2658(23)00334-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wakao, Norimitsu |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Cervicobrachial pain frequently affects the quality of life (QOL) of the general public and has a significant economic impact on the health care systems of various countries. There are a number of treatment options for this disease, including widely-used drug therapy, but the effectiveness of each option is indeterminate, and there have been no published cost-effectiveness analysis studies so far. This prospective observational study aimed to examine the cost-effectiveness of drug treatment for cervicobrachial symptoms | ||
| 520 | |a METHODS: A 6-month medication regimen for each of five frequently-prescribed drugs for cervicobrachial symptoms was administered to 322 patients at 24 centers in Japan. Outcome measures, including of the EuroQol Group 5D, Short Form-8, and Visual Analog Scale (VAS), were investigated at baseline and every month thereafter. Incremental cost-effectiveness ratios (ICERs) of the drug cost to quality-adjusted life years (QALYs) were calculated. A stratified analysis of patient characteristics was also performed to identify baseline factors potentially affecting cost-effectiveness | ||
| 520 | |a RESULTS: The ICER of entire drug treatment for cervicobrachial symptoms was 7,491,640 yen. Compared with the reference willingness-to-pay, the ICER was assumed to not be cost-effective. A certain number of QALYs were gained during the first 3 months after the treatment intervention, but almost no QALYs were gained during the following 3 months. Stratified analysis showed that cost-effectiveness was extremely low for patients with high baseline VAS and high QOL | ||
| 520 | |a CONCLUSIONS: The available medications for cervicobrachial symptoms did not have excellent cost-effectiveness. Although a certain number of QALYs were gained during the first 3 months after medication, no QALYs were gained in the latter half of the study period, suggesting that it is not advisable to continue the medication needlessly | ||
| 520 | |a LEVEL OF EVIDENCE: II, prospective cohort study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cervicobrachial symptoms | |
| 650 | 4 | |a Cost effectiveness | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a ICER | |
| 650 | 4 | |a QALY | |
| 650 | 4 | |a QOL | |
| 700 | 1 | |a Furuya, Takeo |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshii, Toshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Arima, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamato, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Imagama, Shiro |e verfasserin |4 aut | |
| 700 | 1 | |a Imajo, Yasuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Miyagi, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kanbara, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Iizuka, Yoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Chikuda, Hirotaka |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Kazuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsushima, Mikito |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazaki, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yagi, Mitsuru |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Takahata, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hongo, Michio |e verfasserin |4 aut | |
| 700 | 1 | |a Koda, Masao |e verfasserin |4 aut | |
| 700 | 1 | |a Nagata, Keiji |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Kanji |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Akinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kaito, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Murotani, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Miyakoshi, Naohisa |e verfasserin |4 aut | |
| 700 | 1 | |a Hashizume, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuyama, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Mamoru |e verfasserin |4 aut | |
| 700 | 1 | |a Haro, Hirotaka |e verfasserin |4 aut | |
| 700 | 0 | |a Project Committee of the Japanese Society for Spine Surgery and Related Research (JSSR) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association |d 1998 |g (2023) vom: 26. Dez. |w (DE-627)NLM095454527 |x 0949-2658 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:26 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jos.2023.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 26 |c 12 | ||